Recombinant Human Diacylglycerol kinase epsilon (DGKE)

What makes DGKE structurally unique among diacylglycerol kinase isoforms?

DGKE stands out among the diacylglycerol kinase family as the only isoform without identifiable structural motifs outside its conserved catalytic domain and C1 domains. Unlike other isoforms that contain various structural elements such as calcium-binding EF hand motifs (found in α, β, and γ), pleckstrin homology domains (found in δ, η, and κ), or sterile alpha motifs (found in δ and η), DGKE has a comparatively simple structure .

The enzyme contains a unique functional domain homologous to the arachidonic acid binding site of lipoxygenase, called the lipoxygenase (LOX)-like motif, located at the C-terminal accessory domain. This motif is characterized by a distinctive amino acid sequence: L-X(3-4)-R-X(2)-L-X(4)-G, where X(n) represents n residues of any amino acid . Site-specific mutations in this region result in loss of enzymatic activity or arachidonoyl specificity, highlighting its functional importance.

How does DGKE differ functionally from other DGK isoforms?

DGKE exhibits several distinctive functional characteristics:

• Substrate selectivity: DGKE is uniquely selective for both acyl chains in diacylglycerol (DAG), with a strong preference for 1-stearoyl-2-arachidonoyl-DAG. Its activity is approximately 5-fold higher with 18:0/20:4-DAG compared to 18:0/18:2-DAG, and it is unable to phosphorylate 18:0/22:6-DAG .

• Product inhibition: DGKE is the only DGK isoform showing competitive inhibition by its product, phosphatidic acid (PA). This inhibition is also selective for a combination of the sn-1 and sn-2 acyl chains, preferring 1-stearoyl-2-arachidonoyl-PA .

• Membrane association: DGKE displays properties of both integral and peripheral membrane proteins, with its hydrophobic segment capable of forming either a classic transmembrane helix or a U-shaped re-entrant helix .

• Regulatory mechanism: DGKE appears to have a unique regulatory mechanism where its dual acyl chain selectivity negatively regulates its enzymatic activity, ensuring it remains committed to the phosphatidylinositol (PI) turnover cycle .

What is the tissue distribution of DGKE and how can it be detected in laboratory settings?

DGKE is primarily expressed in neurons and testis, with varying expression levels in other tissues . For laboratory detection, several methods are effective:

• Western blot: Human DGKE can be detected in cell lines such as Caki-2 (human clear cell carcinoma epithelial cells) and K562 (human chronic myelogenous leukemia cells), while mouse DGKE can be detected in NIH-3T3 embryonic fibroblasts. Using specific antibodies like Sheep Anti-Human DGK-ε, the protein appears as a band at approximately 65 kDa under reducing conditions .

• Immunohistochemistry: DGKE can be visualized in tissue sections using appropriate antibodies. In human brainstem sections, for example, DGKE staining localizes to neuronal cell bodies and processes .

• Direct ELISA: Recombinant human DGKE can be detected using direct enzyme-linked immunosorbent assays .

What are the primary roles of DGKE in cellular signaling pathways?

DGKE plays critical roles in cellular signaling:

• Phosphatidylinositol cycle regulation: DGKE has an important function in the phosphatidylinositol (PI) cycle, which mediates many cellular events by controlling the metabolism of lipid second messengers .

• DAG signaling modulation: By phosphorylating DAG to produce PA, DGKE downregulates DAG signaling that results from inositol cycling .

• Substrate enrichment mechanism: While the kinetic difference for closely related lipid species may be small, the cyclical nature of PI turnover leads to significant enrichment of 1-stearoyl-2-arachidonoyl PI species .

• Pathway commitment: The dual acyl chain selectivity of DGKE for both its substrate (DAG) and inhibitor (PA) ensures that the enzyme remains committed to the PI turnover cycle, representing a novel mechanism of enzyme regulation within a signaling pathway .

What pathological conditions are associated with DGKE mutations?

DGKE mutations are associated with several renal pathologies:

• Atypical hemolytic uremic syndrome (aHUS): Mutations in DGKE can lead to aHUS characterized by thrombotic microangiopathy .

• Membranoproliferative glomerulonephritis (MPGN): DGKE mutations give an MPGN-like appearance to varying extents .

• Combined phenotypes: Some patients display features of both aHUS and nephrotic syndrome .

• Complement-related phenotypes: While initially DGKE-associated diseases were thought to show normal complement levels, expanded clinical phenotypes include hypocomplementemic aHUS with significant serum complement activation and consumption of complement fraction C3 .

The incidence of DGKE aHUS is approximately 0.009/million/year, while DGKE MPGN occurs at about 0.006/million/year, giving a combined incidence of 0.015/million/year .

How do DGKE mutations affect protein structure and function in atypical hemolytic uremic syndrome?

DGKE mutations in aHUS patients cause structural and functional alterations that disrupt normal enzyme activity:

• Conformational changes: Mutations yield abnormal crystal structures and conformations, leading to dysregulation of downstream signaling . Bioinformatic analyses suggest that these conformational changes disrupt the binding of DGKE with its partners, contributing to aHUS pathogenesis.

• Types of mutations: Various mutations have been identified, including:

  • Missense mutations (e.g., c.231C>G)

  • Frameshift mutations (e.g., c.790_791delTG)

  • Truncating mutations (e.g., p.K101X)

• Ethnicity-specific variants: Different racial groups may have different DGKE variants. For example, a novel compound heterozygous mutation was identified in a Chinese consanguineous family, expanding the spectrum of sequence variants in the DGKE gene .

• Functional impact: While DGKE has not been directly implicated in the complement cascade, mutations potentially lead to a prothrombotic state . Some DGKE mutations result in complement activation, challenging earlier assumptions about the relationship between DGKE and complement systems.

What experimental approaches are most effective for studying DGKE substrate specificity?

Researching DGKE substrate specificity requires specialized techniques:

• Lipid substrate preparation: Synthesize or obtain DAG variants with different acyl chain compositions:

  • 18:0/20:4-DAG (optimal substrate)

  • 18:0/18:2-DAG (reduced activity)

  • 18:0/22:6-DAG (poor substrate)

  • Variants with modified sn-1 positions (16:0, 20:0)

• Enzymatic activity assays: Measure phosphorylation rates using:

  • Purified recombinant DGKE

  • Radioactive ATP (32P-ATP) to track phosphorylation

  • Mixed micelle systems with Triton X-100 for lipid presentation

• Competitive inhibition studies: Assess PA inhibition by:

  • Using various PA species with different acyl chain compositions

  • Determining IC50 values

  • Analyzing Lineweaver-Burk plots to confirm competitive inhibition

• Truncation constructs: Utilize DGKE constructs lacking specific domains:

  • DGKEΔ40 (lacking first 40 N-terminal residues including hydrophobic segment)

  • Compare activity and substrate specificity between truncated and full-length proteins

• Site-directed mutagenesis: Target the LOX-like motif to assess its role in substrate recognition by creating point mutations in the L-X(3-4)-R-X(2)-L-X(4)-G sequence .

What are the challenges in expressing and purifying functional recombinant DGKE?

Researchers face several challenges when working with recombinant DGKE:

• Membrane association issues: DGKE's hydrophobic segment leads to membrane association, creating difficulties in expression and purification. The protein displays properties of both integral and peripheral membrane proteins .

• Stability concerns: Full-length DGKE shows decreased stability following freeze-thaw cycles or at room temperature.

• Self-aggregation tendency: The protein has a tendency to self-aggregate following purification, particularly with full-length constructs .

• Solubility limitations: The hydrophobic nature of DGKE creates solubility issues during purification.

• Expression strategy:

  • Truncation approach: The DGKEΔ40 construct (lacking the first 40 N-terminal residues) retains enzymatic activity and substrate specificity while exhibiting increased stability and solubility compared to full-length DGKE .

  • Expression systems: Mammalian cell expression systems may provide better folding and post-translational modifications than bacterial systems.

  • Fusion tags: Addition of solubility-enhancing tags (MBP, SUMO) can improve expression and purification outcomes.

How do the dual conformations of DGKE's hydrophobic segment impact its function?

DGKE's hydrophobic segment can adopt two stable conformations with functional implications:

• Conformation types:

  • Classic transmembrane helix

  • U-shaped re-entrant helix that enters and leaves the membrane on the same side of the bilayer

• Critical residues: Proline 32 within the hydrophobic segment is crucial for the formation of the U-shaped re-entrant helix and likely plays a role in interconversion between the two conformations .

• Functional relevance:

  • The ability to switch between conformations may allow DGKE to adjust its positioning relative to membrane-bound substrates

  • This conformational flexibility might regulate access to different pools of DAG within the membrane

  • The hydrophobic segment may facilitate interaction with specific membrane microdomains

• Experimental approaches to study conformational states:

  • Site-directed mutagenesis of Pro32

  • Biophysical techniques including circular dichroism and NMR

  • Fluorescence resonance energy transfer (FRET) analyses to monitor conformational changes

  • Molecular dynamics simulations to predict conformational stability

What are the current hypotheses regarding the mechanism of DGKE-associated thrombotic microangiopathy?

Several mechanisms have been proposed to explain how DGKE mutations lead to thrombotic microangiopathy:

• Prothrombotic state hypothesis: DGKE deficiency may create a prothrombotic environment by influencing endothelial cells and platelet function, independent of complement activation .

• Complement activation pathway: Despite initial reports suggesting DGKE mutations do not affect complement, expanded phenotypes include cases with significant complement activation and C3 consumption . This suggests DGKE may interact with complement pathways in some contexts.

• DAG signaling dysregulation: Loss of DGKE function prevents normal phosphorylation of DAG, potentially leading to:

  • Prolonged PKC activation

  • Altered cellular responses to inflammatory stimuli

  • Disrupted vascular endothelial homeostasis

• PI cycle disruption: DGKE mutations may impair the phosphatidylinositol cycle, affecting multiple downstream signaling pathways critical for cellular function and vascular integrity .

• Treatment implications: The mechanism has important therapeutic implications:

  • Complement blockade (e.g., eculizumab) might be ineffective in purely DGKE-mediated cases

  • Plasma infusion therapy has shown efficacy in controlling systemic symptoms and preventing renal failure in some patients with DGKE mutations

What genetic screening approaches are recommended for identifying DGKE mutations in patients with suspected aHUS?

Comprehensive genetic screening for DGKE mutations requires specialized methodologies:

• Next-generation sequencing (NGS) approaches:

  • Targeted exome sequencing: Focus on DGKE and other aHUS-associated genes using platforms such as Illumina NextSeq 500 .

  • Whole-exome sequencing: Particularly useful for consanguineous families to identify homozygous or compound heterozygous mutations .

  • Whole-genome sequencing: When intronic or regulatory region mutations are suspected.

• Homozygosity mapping: Essential for consanguineous families to identify regions containing potential disease-causing genes .

• Mutation confirmation:

  • Sanger sequencing to validate NGS findings

  • Segregation analysis in family members

  • Functional validation of novel variants

• Variant interpretation strategy:

  • Assess population frequency in databases (gnomAD, 1000 Genomes)

  • Evaluate conservation across species

  • Utilize prediction tools (SIFT, PolyPhen-2, MutationTaster)

  • Classify variants according to ACMG guidelines

• Recommended gene panel for comprehensive aHUS screening:

  • DGKE

  • Complement system genes: CFH, CFI, MCP, C3, CFB

  • Coagulation system genes: THBD, PLG

  • Additional genes implicated in thrombotic microangiopathy

How can researchers design CRISPR/Cas9-based models to study DGKE function?

Creating effective CRISPR/Cas9 models for DGKE research requires careful planning:

• Guide RNA design considerations:

  • Target functionally important domains (catalytic domain, LOX-like motif)

  • Design multiple sgRNAs to increase knockout efficiency

  • Avoid off-target effects by using prediction tools

  • Consider knock-in strategies for studying specific mutations identified in patients

• Cell line selection:

  • Endothelial cells (primary or immortalized) are relevant for studying vascular aspects

  • Renal cell lines for kidney-specific effects

  • Neuronal cell lines to investigate DGKE's role in the nervous system

  • Patient-derived iPSCs to model disease in relevant cell types

• Validation approaches:

  • Western blot confirmation of DGKE knockout/mutation

  • Functional assays to assess DAG phosphorylation

  • Sequencing to confirm genomic modifications

  • Off-target analysis using whole-genome sequencing

• Phenotypic assessment:

  • Analyze PI-cycle phospholipids using mass spectrometry

  • Evaluate thrombotic tendencies in endothelial models

  • Measure complement activation in different conditions

  • Assess cell survival, proliferation, and response to stress

• Rescue experiments:

  • Reintroduce wild-type DGKE to confirm phenotype specificity

  • Test different mutant versions to identify critical residues

  • Use truncated constructs to determine domain contributions

What are the recommended protocols for analyzing DGKE expression in tissue samples?

Detecting and quantifying DGKE in tissues requires optimized protocols:

• Immunohistochemistry (IHC) procedure:

  • Tissue preparation: Use immersion fixed paraffin-embedded sections

  • Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0)

  • Primary antibody: Sheep Anti-Human DGKE at 10 μg/mL, incubated overnight at 4°C

  • Detection system: HRP-DAB for visualization with hematoxylin counterstain

  • Expected results: Positive staining in neuronal cell bodies and processes

• Western blot protocol:

  • Sample preparation: Lyse cells or tissues in RIPA buffer with protease inhibitors

  • Gel conditions: Run under reducing conditions using 10% SDS-PAGE

  • Transfer: Use PVDF membrane

  • Antibody concentration: 1 μg/mL of Sheep Anti-Human DGKE

  • Expected band size: ~65 kDa

• qRT-PCR analysis:

  • Design primers spanning exon-exon junctions

  • Use reference genes appropriate for tissue type

  • Perform relative quantification using 2^(-ΔΔCt) method

  • Consider multiple reference genes for normalization

• RNA in situ hybridization:

  • Useful for precise localization in tissues

  • Design probes specific to DGKE mRNA

  • Include positive and negative controls

  • Consider dual labeling with cell-type markers

• Single-cell RNA sequencing:

  • For high-resolution cell-type specific expression patterns

  • Useful in heterogeneous tissues like brain and kidney

  • Can identify cell populations expressing highest DGKE levels

What assays can be used to measure DGKE enzymatic activity in different experimental settings?

Multiple approaches allow researchers to assess DGKE activity:

• Radioactive kinase assay:

  • Substrate preparation: Use 1-stearoyl-2-arachidonoyl-DAG

  • Reaction mixture: DGKE enzyme, [γ-32P]ATP, MgCl2, buffer

  • Analysis: Thin-layer chromatography or lipid extraction

  • Quantification: Scintillation counting or phosphorimaging

  • Advantages: High sensitivity, direct measurement of product formation

• Non-radioactive ATP consumption assays:

  • Coupled enzyme approach: Link ATP consumption to NADH oxidation

  • Detection: Measure absorbance decrease at 340 nm

  • Advantages: Real-time monitoring, no radioactivity

  • Limitations: Indirect measurement, potential interference

• Mass spectrometry-based assays:

  • Approach: Direct measurement of DAG consumption and PA production

  • Quantification: Using internal standards and LC-MS/MS

  • Advantages: Detailed lipid species analysis, high specificity

  • Limitations: Requires specialized equipment, complex sample preparation

• Cellular assays:

  • Transfection: Overexpress DGKE in cultured cells

  • Stimulation: Treat with receptor agonists to activate PI cycle

  • Analysis: Extract and analyze lipids by mass spectrometry

  • Advantages: Physiological context, measures function in intact cells

• Competition assays for inhibitor testing:

  • Use varying concentrations of PA or other potential inhibitors

  • Generate Lineweaver-Burk plots to determine inhibition type

  • Calculate Ki values to quantify inhibitor potency

How can researchers investigate the potential therapeutic applications of targeting DGKE in renal diseases?

Exploring DGKE as a therapeutic target requires systematic approaches:

• Therapeutic strategy development:

  • For loss-of-function mutations: Gene therapy to restore DGKE function

  • For dysregulated pathways: Small molecule modulators of downstream effectors

  • For complement activation cases: Combination therapy with complement inhibitors

  • For thrombotic phenotypes: Anticoagulant or antiplatelet approaches

• Treatment response assessment:

  • Monitor clinical parameters: serum creatinine, proteinuria, hematological variables

  • Track complement activation markers

  • Assess thrombotic markers

  • Longitudinal follow-up for disease recurrence or progression

• Treatment efficacy data from case studies:

  • Plasma infusion therapy has shown efficacy in controlling systemic symptoms and preventing renal failure in DGKE mutation patients

  • Evaluate complement blockade (eculizumab) efficacy in different DGKE mutation contexts

• Preclinical model development:

  • Generate DGKE knockout mice

  • Create knock-in models with specific patient mutations

  • Develop cell-based systems for high-throughput screening

• Biomarker identification:

  • Discover biomarkers predicting treatment response

  • Identify markers for early disease detection

  • Develop prognostic indicators for disease progression